STENTYS recruits Country Managers for France and Italy

STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it is starting the marketing of the STENTYS stents in France and Italy.

STENTYS stents have been available in Germany and the Netherlands since 2010 and have been marketed in Scandinavia, Spain, Switzerland and Poland since the first quarter of 2011: they are henceforth also available in both France and Italy.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, stated: “Our commercial development is in line with our business plan. France in particular is a major market for stents, and we are very pleased that the 100,000 patients who suffer from a heart attack there each year will be able to be treated with STENTYS stents.”

STENTYS published a +72.3% increase in revenues in the 1st quarter of 2011 compared to the 4th quarter of 2010. The availability of the STENTYS stents in France and Italy should provide a contribution to Group revenues from the end of 2011.

- **Next press release**

STENTYS’ revenues for the 1st half of 2011 will be published on 26 July, 2011.

**About STENTYS:**

Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries.

*More information on [www.stentys.com](http://www.stentys.com)*

**Stentys**  
Stanislas Piot  
CFO  
Tel.: +33 (0)1 44 53 99 42  
stan.p@stentys.com

**NewCap.**  
Financial Communication / Investor & Press Relations  
Axelle Vuillermet / Pierre Laurent  
Tel.: +33 (0)1 44 71 94 94  
stentys@newcap.fr

STENTYS is listed on Compartment C of the NYSE Euronext Paris  
ISIN: FR0010949404 – Ticker: STNT